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ORIGINAL ARTICLE
Introduction: Lung cancer contains a small population of cancer 
stem cells that contribute to its initiation and progression. We inves-
tigated the biological function and clinical significance of aldehyde 
dehydrogenase 1A1 (ALDH1A1) in non–small-cell lung carcinoma 
(NSCLC).
Methods: ALDH1A1 assay or small interfering RNA transfection 
was employed to isolate ALDH1A1+ cells or knock down ALDH1A1 
expression in H2087 cells, respectively. Biological functions of 
ALDH1A1+ and ALDH1A1 silenced cells were investigated using in 
vitro and in vivo methods. ALDH1A1 expression was analyzed using 
immunohistochemistry on tissue microarrays with 179 lung cancer 
tissues and 26 normal lung tissues.
Results: The abilities of clone formation, proliferation, cell growth, 
and migration were increased in ALDH1A1+ and ALDH1A1 
silenced cells. ALDH1A1+ lung cancer cells initiated tumors that 
resembled the histopathologic characteristics and heterogeneity of 
the parental lung cancer cells in mice. The silencing of ALDH1A1 
expression in H2087 lung cancer cells inhibited cell proliferation and 
migration significantly. ALDH1A1 was expressed in 42% of normal 
lung tissues (11 of 26), with strong expression in the basal cells and 
globular cells of the normal bronchus and weak expression in the 
alveolar epithelial cells. Compared with normal lung tissues, 45% 
of NSCLC samples (81 of 179) were read as positive for ALDH1A1. 
Positive ALDH1A1 expression was correlated with patients’ smok-
ing status (p = 0.022), lymph-node metastasis (p = 0.006), clinical 
stage (p = 0.004), and a decreased overall survival time (p < 0.001). 
Positive ALDH1A1 expression in lung cancer tissues was an inde-
pendent prognostic factor for NSCLC (odds ratio = 5.232, p < 0.001).
Conclusion: Elucidating the biological functions of ALDH1A1 
could be helpful in studying lung tumorigenesis and for developing 
new therapeutic approaches. 
Key Words: ALDH1A1, ALDEFLUOR assay, Small interfering 
RNA transfection, Tissue microarray, Prognosis.
(J Thorac Oncol 2012;7: 1235–1245)
Lung tumors contain a population of cells that possess can-cer stem-cell (CSC) properties. Not all cancer cells in solid 
tumors have a similar ability to drive tumor formation.1 In 
many cases, only a small subpopulation of cells have the abil-
ity to form new tumors.2
The strategy of using Fluorescence Activating Cell 
Sorter (FACS) by the expression of stem-cell–specific cell-
surface markers has been proven successful in several solid 
tumors, such as breast3, brain4, and colon cancers5. In lung 
cancer, both CD133 and CD44 have been used to isolate stem 
cells, but the specificity of these two markers is uncertain.6 It 
was reported that both CD133+ and CD133− metastatic lung 
cancer cells can initiate xenograft tumors.7 Thus, additional 
specific stem-cell markers need to be discovered and their 
biological functions elucidated.
A promising new marker for CSCs, aldehyde dehydro-
genase 1 (ALDH1A1), is a detoxifying enzyme that oxidizes 
intracellular aldehydes and thereby confers resistance to alkyl-
ating agents. ALDH1A1 also converts retinol to retinoic acid, 
a modulator of cell proliferation, which may also modulate 
CSC proliferation.8 ALDH1A1 has been used for selecting 
stem-like tumor cells in several non–small-cell lung carcinoma 
(NSCLC) cell lines,9 and increased ALDH1A1 expression is 
associated with poor survival in a cohort of NSCLC patients.10
In the present study, we explored the tumorigenic capac-
ity of ALDH1A1+ lung cancer cells and investigated its bio-
logical functions in lung cancer development and progression. 
We also analyzed the prognostic role of ALDH1A1 in NSCLC 
and its association with patient prognosis.
PATIENTS AND METHODS
Patient Parameters
One hundred and seventy-nine lung adenocarcinoma 
patients treated in Nanfang Hospital in Guangzhou 
China from 2000 to 2010 were selected for this study. 
According to the International Association for the Study 
of Lung Cancer/American Thoracic Society/European 
Respiratory Society pathologic classification,11,12 NSCLC 
included adenocarcinoma and squamous-cell carcinomas. 
NSCLCs were also classified as well, moderately or poorly 
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differentiated tumors. The inclusion criteria for this study 
are as follows: (1) NSCLC, (2) patients had no radiotherapy 
or chemotherapy, (3) patient follow-up data of 6 months or 
greater were available, and (4) an adequate paraffin block was 
available for analysis. The clinicopathologic characteristics, 
defined by World Health Organization criteria,13,14 included 
patients’ sex, smoking status, tumor location, tumor subtype, 
tumor differentiation, lymph-node metastasis, tumor size, 
and stage (Table 1).
Specimens from these patients were obtained from the 
Department of Pathology and the Department of Thoracic 
Surgery in Nanfang Hospital. The specimens included tumor 
tissues from 82 primary lung adenocarcinomas and 97 pri-
mary squamous-cell lung carcinomas. Twenty-six snap frozen 
fresh tumor samples and matched normal lung tissues (5 cm 
from the tumor) obtained from among the 179 specimens were 
also available for the study.
The median follow-up time after tumor removal, 
defined as the overall survival (OS) in our study, was 49.2 
months (range, 6–114 months). At the time of censoring the 
data, the follow-up information of 62 patients (35%) was lost 
because of death or other reasons. Written informed consent 
was obtained from all patients according to the protocols of 
the Southern Medical University Ethnics Committee.
Cell Line and Culture
H2087 lung cancer cells were obtained from American 
Type Culture Collection (ATCC; Manassas, VA). The cells 
were maintained in RPMI 1640 medium supplemented with 
1% penicillin/streptomycin and 10% fetal bovine serum in 
5% CO
2
, at 37°C. The cells were harvested when they were 
in the logarithmic phase of growth for use in the following 
experiments.
Isolation of ALDH1A1+ Cell Population by 
ALDEFLUOR Assay and FACS
An ALDH1A1 kit (StemCell Technologies, Durham, 
NC) optimized for interaction with human ALDH1A1 was 
used to identify ALDH1A1+ cells, as previously described.15 
Briefly, the brightly fluorescent ALDH1A1+ expressing cells 
were detected using an Aria cell sorter (BD Biosciences, San 
Jose, CA). Side-scatter and forward-scatter profiles were 
used to reduce cell doublets. Nonviable cells were elimi-
nated using the viability dye 4′, 6-diamidino-2-phenylindole 
(Sigma, St. Louis, MO). Specific ALDH1A1 activity was 
based on the difference between the presence or absence of 
the ALDEFLUOR inhibitor diethylaminobenzaldehyde. Data 
were analyzed using Cell Quest software (BD Biosciences, 
San Jose, CA). Each experiment was repeated three times. 
Unsorted, ALDH1A1+, and ALDH1A1− H2087 lung cancer 
cells were used in consecutive studies.
Immunohistochemistry and 
Immunofluorescence Microscopy
Immunohistochemistry. Four representative tissue cores 
from each of the 179 tumor tissues and 26 normal lung tissues 
were selected to construct tissue microarrays (TMA).16 TMA 
slides were stained with the primary antibody to rabbit antihu-
man ALDH1A1 [EP1933Y] monoclonal antibody (Abcam) 
based on the standard streptavidin-biotin complex method. 
Sections were deparaffinized with xylene, rehydrated with a 
graded series of ethanol, and rinsed in phosphate-buffered saline 
(PBS). Deparaffinized sections were treated with 3% hydrogen 
peroxide to inactivate endogenous peroxidase. The sections were 
blocked with normal nonimmune serum for 30 minutes at 37°C 
and then incubated with ALDH1A1 antibody (1:200) at 4°C 
for 12 hours. The sections were washed three times in PBS and 
treated with biotin-conjugated secondary antibody (ZhongShan 
Golden Bridge Biotechnology Co. Ltd., Beijing, China) for 
30 minutes at room temperature. Antibody localization was 
enhanced using a peroxidase reaction with 3, 3′-diaminoben-
zidine tetrahydrochloride (DAB, ZhongShan Golden Bridge 
Biotechnology Co. Ltd.). Mouse liver tissues were used as posi-
tive controls for ALDH1A1 staining. PBS was used to replace 
the primary antibody and thus served as a negative control.
Analysis of IHC Slides
The samples were analyzed under a 40× objective lens 
using a BX51 light microscope (Olympus, Tokyo, Japan). 
Twenty fields were randomly selected within four randomly 
chosen representative tissue cores from each specimen on the 
TMA. In total, 200 tumor cells were observed. Those with dark 
brown particles in the cytoplasm were regarded as positive 
protein expressions. ALDH1A1 immunohistochemistry (IHC) 
staining was recorded as: no expression (absent staining = 0), 
low expression (30% or more of tumor cells with weak 
TABLE 1.  Clinicopathologic Characteristics of Patients With 
Lung Cancer
Characteristics All Patients (N = 179) (%)
Sex
 Male 112 (63)
 Female 67 (37)
Smoking status
 Nonsmoker 74 (41)
 Smoker 105 (59)
Tumor location
 Central 90 (50)
 Peripheral 89 (50)
Tumor subtypes
 Adenocarcinoma 82 (46)
 Squamous-cell carcinoma 97 (54)
Differentiation
 High 81 (45)
 Moderate–poor 98 (55)
Lymph-node metastasis
 Yes 97 (54)
 No 82 (46)
Tumor size
 >3cm 74 (41)
 <3cm 105 (59)
Stage
 I–II 81 (45)
 III–IV 98 (55)
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staining intensity = 1), or high expression (30% or more of 
tumor cells with strong staining intensity = 2). No expression 
was regarded as negative and low or high expression as positive.
Immunofluorescent Microscopy
Immunofluorescence labeling of ALDH1A1 was car-
ried out on FACS sorted and small interfering RNA (siRNA) 
transfected H2087 lung cancer cells. Briefly, the cells were 
stained with ALDH1A1 antibody (1:200), followed by 
fluorescently conjugated IgG (1:1000, Abcam), and exam-
ined using a BX51 microscope adapted for epifluorescence 
(Olympus). Each batch of slides contained a positive and a 
negative control.
Electron Microscopy
FACS-sorted and siRNA-transfected H2087 lung cancer 
cells were cultured on coverslips and fixed with 2.5% glutar-
aldehyde overnight at 4°C. The coverslips were washed three 
times in PBS, dehydrated through a series of graded etha-
nol, and then critical point dried at room temperature before 
being glued onto the specimen stage for observation. The cells 
were detected using a Hitachi S-3000N Scanning Electron 
Microscope (SEM; Hitachi, Tokyo, Japan). Images were taken 
at the magnification of ×2000.
siRNA Mediated Gene Silencing of ALDH1A1
Expression of human ALDH1A1 was knocked 
down with siRNA duplexes specifically targeting human 
ALDH1A1 messenger RNA (mRNA). Transfection of 
siRNA was performed using Oligofectamine (Invitrogen, 
Carlsbad, CA). The target sequences for human ALDH1A1 
mRNA were as follows: 5′-TTGCTATGGCGTGGTAAGT-3′, 
5′-GACTTACCTGTCCTACTCA-3′. Nontargeting siRNA 
pool (D-001206-13-05; Dharmacon, Fisher Scientific, 
Pittsburgh, PA) was used as a negative control.
Exponential growth phase cells were plated in 6-well 
plates at a density of 0.5 × 105 cells/ml, cultured for 24 hours, 
and transfected with 1 μg of siRNA in reduced serum medium 
(OPTI-MEM-I; Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol, at 30% to 50% confluence. Cells 
were harvested 72 hours post transfection (PT). The RNA and 
protein were extracted and analyzed, respectively.
Quantitative Real-Time Reverse Transcription-
Polymerase Chain Reaction Analysis
Total RNA from siRNA-transfected H2087 cells were 
extracted using TRIzol reagent, and first strand cDNA was 
synthesized using 2 μg of total RNA treated with Moloney 
murine leukemia virus reverse transcriptase (Promega, 
Madison, WI) according to the manufacturer’s instructions. 
Quantitative real-time reverse transcription-polymerase 
chain reaction (RT-PCR) analysis was performed in tripli-
cate with Power PCR SYBR Green Master Mix (Applied 
Biosystems, Carlsbad, CA) using the ABI PRISM 7500 
FAST Real-TIME PCR System (Applied Biosystems) with 
results normalized to β-actin (ACTB) expression. The 
ΔΔC
T
 method was used to calculate relative expression. 
Primer sequences used in RT-PCR for ALDH1A1 were 
(F) 5′-TCGTCTGCTGCTGGCGACAA-3′ and (R) 
5′-AGCCCAACCTGCACAGTAGCG-3′ and ACTB were 
(F) 5′-CGCCAGCTCACCATGGATGATGAT-3′, and (R) 
5′-TCTCTTGCTCTGGGCCTCGTCG -3′.
Western Blot Analysis
Cell lysates were used for Western blot analysis to dem-
onstrate changes in ALDH1A1 protein levels. Lysates from 
each experimental group were separated in parallel on two 10% 
denaturing sodium dodecyl sulfate-polyacrylamide gels, trans-
ferred onto nitrocellulose membranes, blocked with 5% nonfat 
milk in 0.1% tris buffered saline with Tween-20, and probed 
using rabbit antihuman ALDH1A1 [EP1933Y] monoclonal 
antibody (Abcam). Blots were incubated with the primary anti-
body at 1:2000 dilution at 4°C overnight. After washing, the 
secondary antibody (horseradish peroxidase-labeled IgG anti-
rabbit antibody, Invitrogen) was used at 1:3000 dilution for 1 
hour at room temperature. The supersignal-enhanced chemolu-
minescent substrate (Pierce Biotechnology, Inc., Rockford, IL) 
was applied to the probed membrane and exposed for 10 min-
utes before the protein bands were visualized on radiograph 
films (Super Rx, Fuji Photo Film, Tokyo, Japan).
Cell-Proliferation Assay
Cell-proliferation analysis was measured in triplicate 
using a CellTiter 96 Non-Radioactive Cell Proliferation Assay 
Kit (Promega) following the manufacturer’s protocols. Briefly, 
FACS-sorted and siRNA-transfected H2087 cells were plated 
at the following densities: 4 × 103, 6 × 103, 8 × 103, 10 × 103, 
and 12 × 103 cells per well in 96-well plates and incubated 
overnight at 37°C in a humidified, 5% CO
2
 cell-culture incu-
bator. Fifteen microliters of the dye solution was added to each 
well, and the plates were incubated for 4 hours at 37°C in a 
humidified, 5% CO
2
 cell-culture incubator before 100 μl of the 
Solubilization Solution/Stop Mix (Promega) was added and 
incubated for 1 hour at 37°C. The absorbance value (optical 
density) of each well was recorded at 570 nm using a micro-
plate spectrophotometer (BioTek, Beijing, China). All experi-
ments were repeated three times.
In Vitro Plate-Colony Formation Assay
Unsorted, ALDH1A1+ and ALDH1A1− H2087 lung 
cancer cells were plated at a density of 200 cells per well in a 
6-well tissue culture dish, as described previously.10 Colonies 
with 50 cells or more were scored after 2 weeks. Plate-colony 
formation efficiency = (number of colonies/number of cells 
inoculated) × 100%. Wells with no cells inoculated were used 
as negative controls. For each group of cells, triplicate sam-
ples were used and clones were counted in a blind manner by 
two individuals.
In Vitro Migration Assay
FACS-sorted and siRNA-transfected H2087 cells in 
serum-free medium (1 × 106 cells/ml) were added to the top 
chamber of 24-well transwell plates (8-mm pore size; Corning 
Star, Cambridge, Massachusetts). The bottom chamber was 
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prepared with 600 μl of complete medium with 10% fetal 
bovine serum. The assembled chamber was incubated at 37°C 
in a humidified, 5% CO
2
 cell-culture incubator for 24 hours. The 
cells on top of the chamber membrane were gently wiped off 
with a cotton swab, and cells that had migrated and stuck to the 
lower surface of the membrane were fixed with 10% formalin 
and stained with hematoxylin and eosin (H&E) for visualization. 
For quantification, the cells were counted under a BX51 light 
microscope (Olympus) in five randomly selected fields (original 
magnification, ×200). At least four chambers from each of the 
three independent experiments were analyzed.
Cell-Cycle Analysis Using Flow Cytometry
Cells were harvested at an exponential growth phase, 
and single-cell suspensions containing 1 × 106 cells were fixed 
with 70% alcohol. The cell cycle was determined using prop-
idium iodide (Sigma) staining for nuclei. The fluorescence of 
DNA-bound propidium iodide in cells was measured with a 
FACScan flow cytometer (BD Biosciences, Franklin Lakes, 
NJ). The results were analyzed with the ModFit 3.0 software 
(Verity Software House, Topsham, ME). All experiments were 
repeated three times.
In Vivo Studies of Tumorigenicity
Female balb/c nude mice, 5 to 6 weeks old, that weighed 
10 g, were kept in the Animal Center of Nanfang Hospital, 
Guangzhou, China according to the policies of the Committee 
for Animal Usage. The mice were maintained in laminar flow 
rooms with temperature and humidity constant. The mice had 
free access to standard chow and water. Unsorted, ALDH1A1+ 
and ALDH1A1− H2087 lung cancer cells were injected sub-
cutaneously into the left flanks of 10 balb/c nude mice in a 
total volume of 100 μl (105, 104, and 103 unsorted cells; 105, 
104, and 103 ALDH1A1+ cells; 105, 104, and 103 ALDH1A1− 
cells). Experiments were performed in triplicate. Nonviable 
cells were eliminated using the viability dye 4′, 6-diamidino-
2-phenylindole (Invitrogen). When the tumors reached a size 
greater than 1.0 cm, the animals were humanely killed with 
pentobarbital sodium (50 mg/kg; Sigma) to avoid central 
tumor necrosis and undue distress. Tumor volume was calcu-
lated as (W2 × L)/2. H&E and IHC with ALDH1A1 staining 
were performed on mouse tumor specimens from the three 
groups.
Statistical Analysis
Correlations between ALDH1A1 expression and clini-
copathologic charateristics were analyzed using two-sided 
Fisher’s exact test. Overall patient survival was calculated 
from the time of surgery to the time of death or to the time 
of last follow-up, at which point the data were censored. OS 
curves were generated using the Kaplan-Meier method, and 
the log-rank test was used to evaluate the difference between 
positive and negative ALDH1A1 expression subgroups. SPSS 
13.0 (SPSS Inc., Chicago, IL) was used for all statistical analy-
sis. The independent prognostic significance of the ALDH1A1 
expression status was determined using the Cox proportional 
hazards model for multivariate analysis. A p value less than 
0.05 was regarded as statistically significant.
RESULTS
Increased Expression of ALDH1A1 Was 
Correlated With Tumor Progression and Poor 
Prognosis of Lung Cancer
The expression and cytoplasmic localization of 
ALDH1A1 were determined by IHC analysis in 179 lung can-
cer tissues and 26 normal lung tissues (Fig. 1A). ALDH1A1 
was expressed in 42% of normal lung tissues (11 of 26), 
with strong expression in the basal cells and globular cells 
of the normal bronchus and weak expression in the alveo-
lar epithelial cells. Compared with normal lung tissues, 45% 
of NSCLC samples (81 of 179) were read as positive for 
ALDH1A1. Western blot analyses showed that ALDH1A1 
expression level was higher in lung adenocarcinoma (Fig. 
1B), and squamous-cell carcinoma tissues (Fig. 1C) compared 
with corresponding normal lung tissues. Positive ALDH1A1 
expression was correlated with patients’ smoking status 
(p = 0.022), lymph-node metastasis (p = 0.006), and clinical 
stage (p = 0.004) (Table 2). Kaplan-Meier survival analysis 
revealed that patients with positive ALDH1A1 expression 
had a shorter OS time compared with patients with negative 
ALDH1A1 expression (34.3 versus 67.2, p < 0.001, Fig. 1D). 
Multivariate analysis confirmed positive ALDH1A1 expres-
sion as an independent prognostic factor for NSCLC (odds 
ratio = 5.232, p < 0.001).
ALDH1A1+ Cells Promoted Aggressive 
Phenotypes of Lung Cancer Cells In Vitro
Immunofluorescence analysis confirmed the presence 
of ALDH1A1 in the cytoplasm of H2087 lung cancer cells. 
FACS-sorting results showed the percentage of ALDH1A1+ 
H2087 lung cancer cells was 10.2% (Fig. 2A), which was 
confirmed by Western blot analysis and immunofluorescence 
staining (Fig. 2B and C). ALDH1A1+ cells increased 
the ability of cancer cells to grow, proliferate, and form 
colonies compared with ALDH1A1− cells (Fig. 2D and E). 
It was indicated in migration assay that ALDH1A1+ cells 
caused a significant increase in cell motility compared with 
ALDH1A1− cells (Fig. 2F). Cell-cycle analysis with flow 
cytometry revealed that the proportion of cells arrested in 
the S and G2/M phase amounted to 50.2% in ALDH1A1+ 
cells, compared with 31.7% in ALDH1A1− cells and 
21.0% in unsorted cells (Fig. 2G). It was shown by light 
microscopy and SEM that ALDH1A1+ lung cancer cells 
exhibited different cellular morphology compared with 
ALDH1A1− cells. In comparison with ALDH1A1− cells, 
ALDH1A1+ cells showed long spindle-shaped form with 
finger-like pseudopods, extending from the cell bodies. 
These results suggest that ALDH1A1+ lung cancer cells play 
a critical role in cell growth, proliferation, migration, and 
cell cycle. Similar results were obtained in three independent 
experiments.
Silencing of ALDH1A1 Inhibited the Aggressive 
Potentialities of H2087 Cells In Vitro
We investigated the role of ALDH1A1 in the aggressive 
potentialities of lung cancer cells in vitro.  Small interfering 
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RNA transfection was employed to knock down ALDH1A1 
expression in H2087 cells, which had high endogenous 
ALDH1A1 expression. The effect of siRNA transfection on 
the expression of ALDH1A1 was confirmed by RT-PCR and 
Western blot analysis. The amount of ALDH1A1 mRNA or 
protein, normalized over ß-actin, was reduced up to 85% 
compared with the negative control cells (Fig. 3A). This 
corresponded to over 50% of the cells being successfully 
knocked down, indicated by immunofluorescence (Fig. 3B). 
In vitro silencing of ALDH1A1 inhibited cell growth 
(Fig. 3C). In parallel to the absence of protein, a significantly 
slower proliferation rate was observed in ALDH1A1 siRNA-
transfected cells compared with negative control cells 
(Fig. 3C). The number of cells arrested in the S phase was 
FIGURE 1. ALDH1A1 expression in lung carcinomas was associated with poor prognosis. A, Expression analysis of ALDH1A1 
protein in normal lung tissues and lung carcinomas using tissue microarrays (left panel: scale bar 100 μm) and the correspond-
ing lower right quadrant magnified images (right panel: scale bar 50 μm) by immunohistochemistry. ALDH1A1 staining was 
localized in the cytoplasm. Aa and Ag, Weak ALDH1A1 expression in the alveolar epithelial cells of normal lung tissues. Ab and 
Ah, Strong ALDH1A1 expression in the basal cells and globular cells of the normal bronchus. Ac and Ai, Moderate ALDH1A1 
expression in squamous-cell lung carcinomas; (Ad and Aj) strong ALDH1A1 expression in squamous-cell lung carcinomas; (Ae 
and Ak) moderate ALDH1A1 expression in lung adenocarcinomas; (Af and Al) strong ALDH1A1 expression in lung adenocar-
cinomas. B, Increased ALDH1A1 levels in human lung adenocarcinomas (Ba) and squamous-cell lung carcinomas (Bb) com-
pared with corresponding normal lung tissues detected by immunoblotting. Expression levels of ALDH1A1 were normalized by 
β-actin. C, Kaplan-Meier survival analysis of overall survival in all patients according to ALDH1A1 expression. The log-rank test 
was used to calculate the p value (p < 0.001). ALDH1A1, aldehyde dehydrogenase 1A1. 
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significantly increased with a corresponding decrease of the 
cell number in G2 phase (Fig. 3D). It was demonstrated in a 
cell-migration assay that depletion of ALDH1A1 in H2087 
cells strongly reduced cell-migration abilities (Fig. 3E), 
suggesting the necessary role of ALDH1A1 in the process 
of cell migration. Light microscopy and SEM showed that 
compared with nontargeting control cells, ALDH1A1 
siRNA-transfected H2087 cells were blunt without finger-
like projections (Fig. 4A-d, 4A-e, 4A-f and Fig. 4B-j, 4B-k, 
4B-l). Similar results were obtained in three independent 
experiments.
ALDH1A1 Promoted Tumor Growth In Vivo
The effect of ALDH1A1 on cancer growth was 
assessed in vivo in mice that received a subcutaneous injec-
tion of unsorted, ALDH1A1+, and ALDH1A1− H2087 lung 
cancer cells. Tumors were larger in the group injected with 
ALDH1A1+ cells, compared with the groups injected with 
either ALDH1A1− or unsorted cells (Fig. 5A). ALDH1A1+ 
cells were at least 100 times more tumorigenic than 
ALDH1A1− and unsorted cells (Fig. 5B). The tumor forma-
tion rate of ALDH1A1+ cells was significantly higher than 
that of ALDH1A1− and unsorted cells (Fig. 5C, p = 0.012). 
H&E staining revealed that the tumor tissues obtained from 
the mice injected with ALDH1A1+ cells recapitulated the 
morphology of lung adenocarcinoma. ALDH1A1 immuno-
histochemical staining of the tumor tissues obtained from the 
mice injected with ALDH1A1+ cells exhibited strong expres-
sion of ALDH1A1 in the cytoplasm of tumor cells. However, 
weak ALDH1A1 expression or no expression was observed 
in the tumor tissues obtained from the mice injected with 
ALDH1A1− cells (Fig. 5D).
DISCUSSION
Cancer stem or stem-like cells were defined functionally 
by the following criteria: high tumorigenicity, self-renewal 
capacity, and the ability to recapitulate the heterogeneity of 
the original primary tumor. There is increasing evidence that 
many human cancers are driven and maintained by CSCs that 
mediate tumor metastasis and contribute to treatment resis-
tance and relapse.17
ALDH1A1 belongs to a family of intracellular 
enzymes that participate in cellular detoxification, differen-
tiation, and drug resistance through the oxidation of cellular 
aldehydes.18 Several lines of evidences have suggested that 
the ALDH isoform ALDH1A1 is a CSC marker. High levels 
of ALDH1A1 are expressed in hematopoietic stem cells19 
and other solid tumors, and are associated with worse clini-
cal outcome.20,21
Evidence for ALDH1A1 as a relevant lung CSC 
marker came in 2008 with the discovery of elevated levels 
of ALDH1A1 protein expression in putative lung stem-cell 
niches during malignant transformation.22,23 In a limited 
study, high levels of ALDH1A1 protein expression cor-
relates with poor patient prognosis, a finding consistent 
with the hypothesis that ALDH1A1+ lung tumor cells are 
enriched in lung CSCs.10,24 It is revealed in the present study 
that ALDH1A1 expression was up-regulated in primary 
NSCLC compared with corresponding normal lung tissues. 
Almost half of the primary tumor specimens analyzed in 
this study lacked ALDH1A1 expression, suggesting these 
tumors might lack CSCs. In 42% of normal lung tissues, 
ALDH1A1 was expressed in the basal cells and globular 
cells along the bronchial epithelium. This indicates that 
basal cells and globular cells might represent the precur-
sor cells, which could possibly evolve into different lung 
carcinoma subtypes. The location and morphology of these 
ALDH1A1 positively stained basal cells are consistent with 
stem cells of the upper airways. It is believed that the basal 
cell fraction includes stem cells.25 Immuno-colabeling of 
ALDH1A1 with other newly developed basal-cell–specific 
markers would be helpful to gain a better understanding of 
pulmonary stem-cell biology. We also observed ALDH1A1 
expression in the stromal cells of all NSCLC specimens. 
The biological significance of this finding is unclear and 
needs further investigation.
Several lines of evidence support that ALDH1A1+ lung 
cancer cells could be enriched in CSCs or stem-like cancer 
cells.26,27 The present study showed that ALDH1A1+ lung 
cancer cells possessed stem-like properties and promoted 
lung cancer progression and development. First, the in vitro 
assays showed that ALDH1A1+ lung cancer cells had higher 
proliferation abilities and clone-formation efficiency than 
TABLE 2. Correlations Between ALDH1A1 Expression and 
Patient Clinicopathologic Characteristics
Characteristics Positive 
ALDH1A1 
Expression 
(N = 81)
Negative 
ALDH1A1 
Expression 
(N = 98)
χ2 p
Sex — — 0.272 0.602
 Male 49 63 — —
 Female 32 35 — —
Smoking status — — 5.211 0.022
 Nonsmoker 26 48 — —
 Smoker 55 50 — —
Tumor location — — 0.146 0.702
 Central 42 48 — —
 Peripheral 39 50 — —
Differentiation — — 1.019 0.313
 High 40 41 — —
 Moderate–poor 41 57 — —
Lymph-node 
metastasis
— — 7.532 0.006
 Yes 53 44 — —
 No 28 54 — —
Tumor size — — 0.588 0.443
 >3cm 36 38 — —
 <3cm 45 60 — —
Stage — — 8.482 0.004
 I–II 27 54 — —
 III–IV 54 44 — —
p values listed are derived from χ2 test.
ALDH1A1, aldehyde dehydrogenase 1A1.
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ALDH1A1− cells. Therefore, ALDH1A1+ H2087 lung 
cancer cells in vitro were highly clonogenic cells. Second, 
ALDH1A1+ cells had greater ability to migrate, which 
was reflected by the typical spindle-like or fibroblastic 
morphology detected by both light and electron microscopy. 
Third, cell-cycle analysis showed that the proportion of cells 
arrested in the S and G2/M phase was higher in ALDH1A1+ 
cells compared with ALDH1A1− cells. Fourth, in vivo 
experiments showed that ALDH1A1+ lung cancer cells were 
at least 100 times more tumorigenic than ALDH1A1− lung 
cancer cells. Furthermore, the xenograft tumors illustrated 
histopathologic patterns similar to those of the primary 
FIGURE 2. ALDH1A1 promoted aggressive phenotypes of lung cancer cells and possessed tumor stem-cell properties in 
vitro. A, FACS analysis of lung cancer cells using the ALDH1A1 assay. The brightly fluorescent ALDH1A1+ cells were detected 
in the green fluorescence channel. The cells incubated with diethylaminobenzaldehyde were used to establish the baseline 
fluorescence of these cells (R1) and define the ALDH1A1 (ALDH1A1+) region (R2). B, Immunoblotting analysis of the unsorted, 
ALDH1A1+, and ALDH1A1− cells, and the relative quantification of ALDH1A1 protein expression. C, Immunofluorescence 
images of the unsorted, ALDH1A1+ and ALDH1A1− cells stained for ALDH1A1 (red), Hoechst33342 (blue) and colocalization 
of the merged images (scale bar  50 μm). D, ALDH1A1+ lung cancer cells formed larger and more colonies as compared with 
the ALDH1A1− cells, by colony-formation assays. ALDH1A1+ cells possessed significantly higher colony-forming efficiency 
compared with ALDH1A1− populations. The unsorted, ALDH1A1+ and ALDH1A1− cells were plated in a 6-well dish.  Two 
weeks after plating, clones were counted and results were presented as the percentage of cloning efficiency (y axis). Columns 
indicate mean from three independent experiments; bars represent SD; *p < 0.05. E, ALDH1A1+ cells promoted cell growth 
and proliferation. Data were presented as mean ± SD of the absorbance value (optical density ) of cells. There was signifi-
cant difference between ALDH1A1+ and ALDH1A1− cells. F, Transwell assay showed that ALDH1A1+ cells had more migra-
tory potentialities as compared with ALDH1A1− cells. G, Cell cycles were detected with flow cytometry analysis. Increased S 
and G2/M phases were observed in ALDH1A1+ cells compared with ALDH1A1− cells. Each bar represented the mean ± SD. 
Results were representative of three independent experiments, *p < 0.05. ALDH1A1, aldehyde dehydrogenase 1A1; FACS, 
Fluorescence Activating Cell Sorter.
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lung cancer cells, implying that the ALDH1A1+ population 
might give rise to heterogeneous lung tumors, which could 
recapitulate the original tumor heterogeneity and possess 
self-renewal capacity.
The present study provides evidence for the clinical 
relevance of CSCs in lung carcinoma and may explain 
why ALDH1A1 positivity in primary tumors may result in 
shortened OS. However, these findings may be limited by the 
retrospective nature of the survival analysis and by the use 
of immunodeficient mice for functional studies because it 
is possible that the mouse microenvironment may not fully 
support the growth of lung cancer cells in the same manner as 
the human microenvironment.
Lung cancer is frequently associated with tobacco 
smoking, and tobacco smoke contains many carcinogens, 
including aldehydes. We found that smokers express higher 
FIGURE 3. In vitro silencing of ALDH1A1 inhibited proliferation and migration of lung cancer cells. A, Oligo siRNA-
mediated knockdown of H2087 cells was confirmed by RT-PCR and Western blot. ALDH1A1 mRNA expression detected 
by RT-PCR and the relative quantification of ALDH1A1 mRNA expression were shown in the left panel. ALDH1A1 protein 
expression detected by Western blot and the relative quantification of ALDH1A1 protein expression were shown in the right 
panel. ALDH1A1 expression was normalized by β-actin expression. B, Immunofluorescence analysis of H2087 lung can-
cer cells transfected with NT siRNA and ALDH1A1 siRNA stained with Hoechst33342 (blue) and ALDH1A1 (red) (scale bar 
50 μm). C, In vitro silencing of the ALDH1A1 gene suppressed cell proliferation. Data were presented as mean ± SD of the 
OD of cells. There was significant difference in the OD between NT siRNA transfected and ALDH1A1 siRNA transfected cells. 
D, Cell cycles were detected with flow cytometry analysis. Increased S phase and decreased G2/M phase were detected in 
the ALDH1A1 siRNA transfected cells compared to the control cells. E, Decreased migratory potentialities were observed 
in ALDH1A1 siRNA transfected cells compared with the NT siRNA control cells. Each bar represents the mean ± SD. Results 
are representative of three independent experiments. *p < 0.05. ALDH1A1, aldehyde dehydrogenase 1A1; siRNA, small 
interfering RNA; RT-PCR, reverse transcription-polymerase chain reaction; mRNA, messenger RNA; OD,  optical density; NT, 
nontargeting control.
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levels of ALDH1A1 than nonsmokers. This is in contrast 
to the report by Sullivan et al.24 where they elucidated that 
positive ALDH1A1 expression was not associated with 
smoking. The present finding suggests that exposure to 
tobacco smoke may be responsible for the elevated expres-
sion of aldehyde dehydrogenase isozymes, which in turn 
can increase the aldehydic carcinogens. It indicates the 
possible association between smoking and the cellular lev-
els of these enzymes. We found that positive ALDH1A1 
expression was associated with lymph-node metastasis and 
late-staged tumors. It is possible that positive ALDH1A1 
tumor cells represent a subset of CSCs with increased 
metastatic potential. These rare cell populations are deter-
minants of clinical outcomes, such as the time to relapse 
or overall patient survival. These findings suggest that 
ALDH1A1 may play a central role in disease initiation, 
relapse, and progression. ALDH1A1 could serve as a bio-
marker predicting long-term outcomes and prognosis in 
NSCLC.28
Our study is limited in that only one lung adenocarci-
noma cell line H2087 was used for the in vitro and in vivo 
analyses. It would be interesting for future studies to isolate 
ALDH1A1+ cells from lung squamous-cell carcinoma cell 
lines. It would provide useful information for elucidating 
the biological roles of ALDH1A1 in the development of 
different subtypes of NSCLC. Further characterization of 
lung CSCs might lead to improved diagnostics and thera-
pies by allowing researchers to better identify and target 
CSCs.25
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FIGURE 4. Light microscopic and 
SEM images of FACS-sorted and 
siRNA-transfected cells. A, Light 
microscopic images of unsorted (a), 
ALDH1A1+ (b), ALDH1A1− (c), NT 
siRNA (d), ALDH1A1 siRNA #1 trans-
fected cells (e), and ALDH1A1 siRNA 
#2 transfected H2087 lung cancer 
cells (f). B, SEM images of unsorted 
(g), ALDH1A1+ (h), ALDH1A1− (i), 
NT siRNA (j), ALDH1A1 siRNA #1 
transfected cells (k), and ALDH1A1 
siRNA #2 transfected H2087 lung 
cancer cells (l). Images were taken 
at the magnification of ×2000. 
ALDH1A1, aldehyde dehydroge-
nase 1A1; SEM, Scanning Electron 
Microscope; SiRNA, small interfering 
RNA; FACS, Fluorescence Activating 
Cell Sorter; NT, nontargeting.
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